维普期刊资源整合服务平台（V6.5）

75篇 您的检索式：作者名="Robert Morrow"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease显示文摘	Sunder Mudaliar Robert R. Henry Arun J. Sanyal Linda Morrow Hanns-Ulrich Marschall Mark Kipnes Luciano Adorini Cathi I. Sciacca Paul Clopton Erin Castelloe Paul Dillon Mark Pruzanski David Shapiro	2013	Gastroenterology2013，，：	7
2	Persistent Epstein-Barr viral load in Epstein-Barr viral na?ve pediatric heart transplant recipients:Risk of late-onset post-transplant lymphoproliferative disease显示文摘AIM To examine the risk of late-onset post-transplant lymphoproliferative disorder(PTLD) in the presence of persisting high Epstein-Barr virus(EBV) in EBV na?ve pediatric heart transplant(HT) recipients. METHODS A retrospective review of the medical records of the 145 pediatric HT recipients who had serial EBV viral load monitoring at our center was performed. We defined EBV naive patients whose EBV serology either IgM or IgG in the blood were negative at the time of HT and excluded passive transmission from mother to child in subjects less than 6 mo of age. RESULTS PTLD was diagnosed in 8 out of 145 patients(5.5%); 6/91(6.5%) in those who were EBV seropositive and 2/54(3.7%) in the EBV na?ve group at the time of HT(P = 0.71). We found 32/145(22%) patients with persistently high EBV load during continuing follow-up; 20/91(22%) in EBV seropositive group vs 12/54(22%) in EBV na?ve group(P = 0.97). There was no significant association between pre-HT serostatus and EBV load after transplant(P > 0.05). In the EBV seropositive group, PTLD was diagnosed in 15%(3/20) of patients with high EBV vs 4.2%(3/71) of patients with low or undetectable EBV load(P = 0.14) whereas in EBV na?ve patients 8.3%(1/12) of those withhigh EBV load and 2.3%(1/42) with low or undetectable EBV load(P = 0.41). There was a highly significant association between occurrence of PTLD in those with high EBV load and duration of follow up(4.3 ± 3.9 years) after HT by Cochran-Armitage test for the entire cohort(P = 0.005). At least one episode of acute rejection occurred in 72%(23/32) of patients with high EBV vs 36%(41/113) patients with low or undetectable EBV after HT(P < 0.05). CONCLUSION There is an association between persistently high EBV load during post-HT follow up and the occurrence of late-onset PTLD in pediatric HT recipients irrespective of serostatus at the time of transplant. The occurrence of allograft rejection increased in patients with high EBV load presumably due to reduction in immunosuppression.	Bibhuti Das Robert Morrow Rong Huang David Fixler	2016	World Journal of Transplantation2016，6，4：	4
3	TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy显示文摘	David A. Morrow Elliott M. Antman Andrew Charlesworth Richard Cairns Sabina A. Murphy James A. de Lemos Robert P. Giugliano Carolyn H. McCabe Eugene Braunwald	2000	Circulation: Journal of the American Heart Association2000，，17：	2
4	Mass spectrometry of prostanoids:F2-isoprostanes produced by non-cyclooxygenase free radical-catalylized mechanism显示文摘	Morrow JD Roberts LJ	1994	Method Enzymol1994，233，2：	1
5	Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial显示文摘	Benjamin M Scirica Marc P Bonaca Eugene Braunwald Gaetano M De Ferrari Daniel Isaza Basil S Lewis Felix Mehrhof Piera A Merlini Sabina A Murphy Marc S Sabatine Michal Tendera Frans Van de Werf Robert Wilcox David A Morrow	2012	The Lancet . 2012 (9850)2012，，9850：	1
6	Measurement of F (2)-isoprostanes as an index of oxidative stress in vivo显示文摘	Roberts LJ Morrow JD	2000	Free Radic Biol Med2000，28，：	1
7	The generation and actions of isoprostanes 显示文摘	Roberts L J Morrow J D	2000	Biochim Biophys Acta2000，1345，2：	1
8	Small heat shock protein expression and functions during development显示文摘	Geneviève Morrow Robert M. Tanguay	2012	International Journal of Biochemistry and Cell Biology2012，，10：	1
9	Measurement of F2-isoprostanes as an index of oxidative stress in vivo显示文摘	Roberts LJ Morrow JD	2000	Free Radical Biology & Medicine2000，28，4：	1
10	Noncycloxygenase oxidative formation of a series of novel prostaglandins:Analytical ramification for measurement of eicosanoids 显示文摘	MORROW J D ARRIS T M ROBERT L J I I	1990	Anal Biochem1990，184，：	1
11	Clinical Implications and Correlates of Q Waves in Patients With ST ‐Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the CLARITY‐TIMI 28 Trial显示文摘	Jonathan W. Waks Marc S. Sabatine Christopher P. Cannon David A. Morrow C. Michael Gibson Stephen D. Wiviott Robert P. Giugliano Sarah Sloan Benjamin M. Scirica	2014	Clin Cardiol2014，，：	1
12	Products of the isoprostane pathway: u- nique bioactive compounds and markers of lipid peroxidat ion 显示文摘	Roberts LJ 2nd Morrow JD	2002	Cell MolLife Sci2002，59，5：	1
13	Products of the isoprostane path- way: unique bioactive compounds and markers of lipid peroxida- tion显示文摘	Roberts LJ 2nd Morrow JD	2002	Cell Mol Life Sci2002，59，5：	1
14	Mass spectrometry of prostanoids:F2-isoprostanesproduced by non-cyclooxygenase free radical-catalyzed mechanism 显示文摘	Morrow JD Roberts LJ 2nd	1994	Methods Enzymol1994，233，：	1
15	Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction显示文摘	C.Michael Gibson Sabina A. Murphy David A. Morrow Julian M. Aroesty Raymond J. Gibbons Steven G. Gourlay Hal V. Barron Robert P. Giugliano Elliott M. Antman Eugene Braunwald	2004	American Heart Journal2004，，2：	1
16	Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual显示文摘	S.Eva Singletary Craig Allred Pandora Ashley Lawrence W Bassett Donald Berry Kirby I Bland Patrick I Borgen Gary M Clark Stephen B Edge Daniel F Hayes Lorie L Hughes Robert V.P Hutter Monica Morrow David L Page Abram Recht Richard L Theriault Ann Thor Don	2003	Surgical Clinics of North America2003，，4：	1
17	Measurement of F2 - isoprostanes as an index of oxidative stress in vivo 显示文摘	Roberts LJ Morrow JD	2000	Free Radical Biology & Medicine2000，28，4：	1
18	Noncyclooxygenase oxidative formation of a series of novel prostaglandins:analyt- ical ramification for measurement of eicosanoids 显示文摘	Morrow JD Harris TM Roberts LJ 2nd	1990	Anal Biochem1990，184，1：	1
19	Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramification for measurement of eicosanoids 显示文摘	Morrow JD Harris TM Roberts II LJ	1990	Anal Biochem1990，184，：	1
20	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure显示文摘	W H. Wilson Tang Gary S. Francis David A. Morrow L Kristin Newby Christopher P. Cannon Robert L. Jesse Alan B. Storrow Robert H. Christenson Robert H. Christenson Fred S. Apple Christopher P. Cannon Gary S. Francis Robert L. Jesse David A. Morrow L Kristi	2007	Circulation2007，，5：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示